Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.

Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

Curr Med Res Opin. 2018 Sep;34(9):1645-1652. doi: 10.1080/03007995.2018.1479246. Epub 2018 Jun 12.


Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.

Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

Clin Ther. 2018 Apr;40(4):628-639.e3. doi: 10.1016/j.clinthera.2018.03.004. Epub 2018 Mar 31.


Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?

Ekinci E, Nathoo S, Korattyil T, Vadhariya A, Zaghloul HA, Niravath PA, Abughosh SM, Trivedi MV.

J Cancer Surviv. 2018 Jun;12(3):348-356. doi: 10.1007/s11764-017-0674-4. Epub 2018 Feb 2. Review.


Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.

Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA.

Adv Ther. 2017 Dec;34(12):2566-2584. doi: 10.1007/s12325-017-0644-2. Epub 2017 Nov 16. Review.


Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.


Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

Supplemental Content

Loading ...
Support Center